# A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors

> **NCT00057473** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** carboplatin + irinotecan
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT00057473
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** — (—)
- **Last updated:** 2011-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057473, "A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00057473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*